Myeloid Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

CAMBRIDGE, Mass., April 15, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30. 

Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat on Monday, April 29, 2024, at 11:30 am ET.  Company management will also participate in one-on-one meetings with investors during the event.

About Myeloid Therapeutics

Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases.  Myeloid is headquartered in Cambridge, MA.

For additional information, please visit, https://www.myeloidtx.com/ and follow us on LinkedIn and X/Twitter.

Investor Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com 

SOURCE Myeloid Therapeutics

Link to original press release can be found here.

BioMediaHub Logo